ESTUDIO FASE II ABIERTO, COMPARATIVO, CRUZADO, SOBRE EFECTO ANTIAGREGANTE PLAQUETARIO DE CRATAESOR® Y ASPIRINA EN VOLUNTARIOS SANOS.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-004845-32-ES

Enrollment

Registered

2006-02-21

Start date

2006-05-09

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Agregación plaquetaria

Interventions

Trade Name: Crataesor Product Name: Crataesor Product Code: 273318-3 Pharmaceutical Form: Trade Name: Adiro 100 Product Name: Adiro 100 Product Code: 751933-1 Pharmaceutical Form: Tablet INN or Prop

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Hombres y mujeres de edad > 18 años =65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: • Enfermedad manifiesta • Ingesta de vitaminas o infusiones de plantas más de 2 veces a la semana en el mes previo.

Design outcomes

Primary

Measure	Time frame
Main Objective: El objetivo principal es determinar el efecto antiagregante plaquetario de Crataesor®;Secondary Objective: Comparar los resultados con el efecto antiagregante plaquetario de aspirina 100 mg / dia.;Primary end point(s):	—

Countries

Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026